Study of MK-1084 and Pembrolizumab for Treating KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer with High PD-L1 Levels | Clinical Trial

Study of MK-1084 and Pembrolizumab for Treating KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer with High PD-L1 Levels | Clinical Trial | Right2Hope